ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

STOK vs NUVB // EV/EBITDA & P/E VALUATION

Stoke Therapeutics Inc. (NASDAQ) VS. Nuvation Bio Inc. (Class A) (NYSE) • 15-METRIC TALLY: STOK 8 — NUVB 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (STOK VS. NUVB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC STOK NUVB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -6.10% -35.00% +28.90 STOK /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 2.64% -10.35% +12.99 STOK /fcf-yield <GO>
Operating Margin -11.20% -60.00% +48.80 STOK /operating-margins <GO>
Net Profit Margin -3.70% -60.00% +56.30 STOK /net-margins <GO>
Revenue Growth (YoY) 180.00% 180.00% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 14.79 0.76 +14.03 STOK /balance-sheet <GO>
Piotroski F-Score Quality 6/9 4/9 +2.00 STOK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.3 42.2 +10.07 STOK /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.70B $1.67B $25.4M STOK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR STOK REV NUVB REV STOK GROSS % NUVB GROSS % STOK FCF NUVB FCF
FY 2025 $184.4M $62.9M — — $44.9M -$173.4M
FY 2024 $36.6M $7.9M — 10.1% -$87.1M -$130.4M
FY 2023 $8.8M $0 — — -$81.1M -$68.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
STOK // BETA —
NUVB // BETA —